Received Jul 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | SC |
possibly administered subcutaneously; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a patient who received DTPa-HBV-IPV (Pediarix) for prophylaxis. On an unknown date, the patient received Pediarix (subcutaneous). On an unknown date, an unknown time after receiving Pediarix, the patient experienced intramuscular formulation administered by other route (Verbatim: possibly administered subcutaneously). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 30-JUN-2025 The clinic supervisor for a pediatric primary care clinic reported that while the medical assistant administered Pediarix was sure it was given intramuscular and the parent who worked in healthcare thought it was given subcutaneously instead, which led to intramuscular formulation administered by other route. The reporter asked was there concern if this is the case.